EUROPA

12.218 patients, 423 sites, finalised 2002
The “European trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease” (EUROPA) study was designed to assess the long-term (three years) effects of perindopril on the reduction of cardiac events in patients with proven stable coronary artery disease, but with no evidence of heart failure.
The EUROPA study included five sub-studies (phase IIb). Each of these sub-studies investigated the effects of perindopril on different aspects of coronary artery disease: endothelial dysfunction, atherosclerosis progression regression, diabetes mellitus, inflammation, thrombosis or neurohormonal activation. Patients were characterised genetically to assess characteristics associated with improved or unfavorable outcome. This randomised, double-blind, placebo-controlled , multicenter trial included 12.218 patients.
The Julius Center was acting as a Regional Coordinating Center and was responsible for the monitoring & project management in five countries (the Netherlands, Czech Republic, Slovakia, Poland and Hungary), with a total of 124 sites. 

Participating countries and number of investigators.

Publications:

Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-8.

Gomma AH, Fox KM, on behalf of the EUROPA Investigators. The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther. 2001;15:169-79.